Kenalog spray (triamcinolone acetonide) / Sun Pharma - LARVOL DELTA

Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: Mayo Clinic; Trial primary completion date: Dec 2016 ➔ Jun 2017

Trial primary completion date • Biosimilar • Demo Pain • Pain

Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears (clinicaltrials.gov) - P1; N=12; Terminated; Sponsor: University of North Carolina, Chapel Hill; N=80 ➔ 12; Not yet recruiting ➔ Terminated

Enrollment change • Trial termination • Biosimilar

Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus (clinicaltrials.gov) - P4; N=30; Completed; Sponsor: Ain Shams University

New P4 trial • Biosimilar • Demo Pain • Immunology • Pain

Sterile endophthalmitis rates and particle size analyses of different formulations of triamcinolone acetonide. (PubMed) - "The rate of SE was the highest with the formulation of TA that had the smallest particle size and highest particle load (number of particles injected). The lowest rate of SE was seen with Kenalog(®)-40, the only TA formulation that contained a benzyl alcohol preservative. The data do not support a principal causative role of benzyl alcohol in the development of TA-induced SE. Instead, the data support the particle theory of TA-induced SE; however, larger-scale, multicenter studies are needed to confirm and expand on these findings."

Journal • Biosimilar • Immunology • Inflammation

Intraarticular Slow-release Triamcinolone Acetate Reduces Allodynia in a Mouse Knee Osteoarthritis Model (ASA 2016) - "Experiment 1: Mice were then given a single IA injection of a commercial TCA suspension (Kenalog-10; Bristol-Myers Squibb) at 10 mg/mL so a 4 μl injection was 40 μg total dose. These data in mice provide rationale for evaluation of HA-based TCA formulations in man to mitigate and control pain for extended durations as compared to HA viscosupplementation and/or TCA injections alone. Such formulations may provide a welcome alternative for long term control of chronic OA pain and may delay the need for knee replacement surgery."

Biosimilar • Demo Pain • Immunology • Oncology • Osteoarthritis • Pain